Printer Friendly

V ClinBio and Camargo Team to Develop Prodrug Technology Platform.

M2 PHARMA-March 8, 2018-V ClinBio and Camargo Team to Develop Prodrug Technology Platform

(C)2018 M2 COMMUNICATIONS

- Cincinnati, Ohio-based biopharmaceutical company V ClinBio Inc. has entered into service agreements with Camargo Pharmaceutical Services, LLC, the company said.

Camargo will provide end-to-end regulatory consulting and strategic development services including pre-investigational new drug (pre-IND) meeting planning and preparations through new drug applications submissions, for V ClinBio's two (2) proprietary medications, CLX-106 and CLX-103, for the treatment of relapsing-remitting multiple sclerosis and ulcerative colitis, respectively.

Both CLX-106 and CLX-103 utilize the proprietary Synergix drug delivery platform, which generates novel prodrugs of approved therapies and conjugates them with long chain fatty acids.

This approach targets two critical points in a disease more efficiently than can be achieved by co-administration or independent dosing of multiple therapies and allows for development via the US 505(b) (2) regulatory pathway.

Camargo is a highly experienced global strategist specializing in drug and fixed-dose combination product development and approval utilizing the regulatory pathway provided for in Section 505(b) (2) of the US Federal Food, Drug, and Cosmetic Act.

CLX-106, a patented novel formulation of MMF conjugated to icosapentaenoic acid for the treatment of RRMS and psoriasis, has demonstrated a highly differentiated profile compared with other MMF prodrugs in development.

CLX-103 is a novel, patented prodrug molecular conjugate of mesalamine, eicosapentaenoic acid and caprylic acid designed to offer incremental benefits over the currently approved 5-ASA formulations for the treatment of ulcerative colitis.

V ClinBio, focused on transforming existing compounds into differentiated new therapeutics, is driving the development of novel drug products for treatment of immune and other related diseases.

It develops new molecular entities (NMEs) using incremental innovation and prodrug technology targeted to provide better pharmacokinetic, pharmacodynamics, physicochemical properties, and to enable the development of known agents for both existing and new indications.

Camargo provide comprehensive drug development services specialized for the 505(b) (2) approval pathway and global equivalent processes.

By assessing the scientific, medical, regulatory, and commercial viability of product development opportunities, the company builds and executes robust development plans. The company works with product developers across more than 25 countries.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 8, 2018
Words:365
Previous Article:Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting.
Next Article:MabVax Therapeutics Meets NASDAQ's USD 1.00 Minimum Bid Price Maintenance Requirement.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters